Target: NS3/4A Protease | Disease State: Hepatitis C

Introduction / Brief Description

Danoprevir is a novel small-molecule inhibitor of the hepatitis C virus NS3/4A protease, jointly invented by Array and InterMune scientists. Roche acquired danoprevir from InterMune in 2010. InterMune has an obligation to make milestone payments to Array based on the selection and progress of danoprevir, as well as royalties on commercial sales of danoprevir. To date, Array has received $4.2 million in milestone payments and has the potential to earn an additional $5 million if all clinical and commercialization milestones for danoprevir are achieved under the agreement. Danoprevir is currently in a Phase 3 clinical trial in China. In December 2016, a New Drug Application for danoprevir was submitted to the China FDA.

Clinical Trials

To learn more about danoprevir clinical trials, click here.  

Publications and Presentations



Journal of Medicinal Chemistry

Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease

Y. Jiang, et al.

These compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview of our clinical trials only.